NanosonicsNNCSF 90 Days Payable is 51.68 as of Dec. 2025, which is 29% above its 10-year median of 40.19. GuruFocus rates NNCSF with a GF Score™ of 90/100 and a GF Value™ of $3.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 795 Medical Devices & Instruments companies, Nanosonics ranks worse than 56.86% on this metric.
Nanosonics's average Accounts Payable for the
six
months ended in Dec. 2025 was $4.6 Mil. Nanosonics's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $16.1 Mil.
Hence, Nanosonics's Days Payable for the
six
months ended in Dec. 2025 was 51.68.
The historical rank and industry rank for Nanosonics's Days Payable or its related term are showing as below:
NNCSF'
s Days Payable Range Over the Past 10 Years
Min: 21.08 Med: 40.19 Max: 62.15
Current: 61.26
During the past 13 years, Nanosonics's highest Days Payable was 62.15. The lowest was 21.08. And the median was 40.19.
NNCSF's Days Payable is ranked worse than 56.86% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs NNCSF: 61.26
Nanosonics's Days Payable
declined
from Dec. 2024 (62.14) to Dec. 2025 (51.68).
It may suggest that Nanosonicsaccelerated paying its suppliers.
Nanosonics Days Payable Related Terms
Nanosonics Days Payable Historical Data
* Premium members only.
The historical data trend for Nanosonics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nanosonics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's Days Payable distribution charts can be found below:
* The bar in red indicates where Nanosonics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Nanosonics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosonics (NNCSF) has a Days Payable of 51.68 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nanosonics and its competitors. This is 29% above median its historical median of 40.19. Over the past decade, Nanosonics' Days Payable has ranged from 21.08 to 62.15. According to the industry distribution chart, Nanosonics ranks #452 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 56.9%.
Is Nanosonics' Days Payable too high?
Nanosonics' current Days Payable of 51.68 is 29% above median its 10-year median of 40.19. Over the past 10 years, this metric has ranged from a low of 21.08 to a high of 62.15. The Medical Devices & Instruments industry median Days Payable is 67.87. Nanosonics' value of 51.68 is 23.9% below this industry median. Based on the distribution chart, Nanosonics ranks #452 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nanosonics has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #452 out of 795 companies for Days Payable. This places Nanosonics in the lower half of its industry. The industry median Days Payable is 67.87. Nanosonics' value of 51.68 is 23.9% below this benchmark. Historically, Nanosonics' own Days Payable has ranged from 21.08 to 62.15 over the past decade. While the company's 10-year median is 40.19 vs. the industry median of 67.87, Nanosonics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosonics's current Days Payable of 51.68 is 23.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nanosonics and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosonics's current Days Payable is 51.68, which is 29% above median its own 10-year median of 40.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (NNCSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.58, compared to a current price of $2.55 — trading 28.8% below its estimated fair value. The current Days Payable is 51.68, which is 29% above median its 10-year median of 40.19 and 23.9% below the Medical Devices & Instruments industry median of 67.87. Nanosonics' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Nanosonics (NNCSF), the current Days Payable is 51.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (NNCSF) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of $2.55 is trading 28.8% below its estimated GF Value™ of $3.58.
GuruFocus considers Nanosonics to be Modestly Undervalued.
Key valuation signals for NNCSF:
Days Payable: 51.68 (29% above median its 10-year median of 40.19)
GF Value™: $3.58 vs. price of $2.55 (28.8% below fair value)
Industry Position: 23.9% below the Medical Devices & Instruments median (#452 of 795)
No single metric tells the full story. See the NNCSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
90GF Score
Get the complete analysis for NNCSF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNCSF has been successfully added to your 
